Related to IP-K Extends Collaborations with Sanofi-Aventis R&D and Novartis Tropical Disease Institute

• Micromet Obtains $11.84M Up Front in Cancer R&D Deal with Sanofi-Aventis
  
• Novartis to Invest $1.25B in Two New Facilities in China
  
• Novartis to Buy 85% of Chinese Vaccines Company for $125M
  
• Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance
  
• Sanofi-Aventis Licenses Intelliject’s Epinephrine Auto-Injector for $25M Up Front
  
• Sanofi-Aventis and AEterna Zentaris Ditch LHRH Antagonist Collaboration
  
• BioMimetic Strengthens Arrangement with Novartis for Exclusive Supply of Recombinant Human Platelet-Derived Growth Factor
  
• Novartis Pays Proteus $24M as Part of Sensor-Based Organ-Transplant Product Partnership
  
• Novartis Gains GenVec’s Preclinical Hearing-Loss and Balance-Disorder Program for $5M
  
• Novartis Nabs Imperial College’s Preclinical Meningitis B Vaccine
  
• Novartis Negotiates Rights to Debiopharm’s Mid-Stage HCV Candidate
  
• Novartis to Evaluate NasVax Adjuvant Technology
  
• Oncodesign to Provide Sanofi-Aventis with Exclusive Cancer Models
  
• Sanofi-Aventis Inks Three-Year Extension to Knowledge-Database Agreement with Aureus
  
• Novartis Signs Four-Year Deal with Horizon for Custom-Generated X-Man Cancer Models
  
• Novartis to Pay $45M Up Front in Cancer Collaboration with Array BioPharma
  
• Vectura Bags $7.5M as Novartis Starts Phase III Development of COPD Therapy
  
• GC-Rise and JS Bio Pharm Sign Separate Agreements for MediGene’s Genital Warts Treatment
  
• Ascenta Enters Deal Potentially Worth $398M with Sanofi-Aventis
  
• Zealand Pharma and Sanofi-Aventis Expand Type 2 Diabetes-Focused Partnership